Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25072040 | 1.00 | NR1H2 (0.52) | NR1H2NAMPTKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL15019245 | 0.86 | NR1H2 (0.58) | NR1H2NAMPTKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL17304839 | 0.84 | NR1H2 (0.56) | NR1H2NAMPTKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL24447236 | 0.84 | NR1H2 (0.56) | NR1H2NAMPTKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL25072069 | 0.84 | NR1H2 (0.51) | NR1H2NAMPTKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL21553441 | 0.84 | NR1H2 (0.54) | NR1H2NAMPTKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL30750567 | 0.82 | NR1H2 (0.55) | NR1H2NAMPTKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL121357 | 0.81 | NR1H2 (0.54) | NR1H2NAMPTKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL24120700 | 0.80 | NR1H2 (0.49) | NR1H2NAMPTKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL20497892 | 0.80 | NR1H2 (0.49) | NR1H2NAMPTKDM4EUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | GENENTECH, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | GENENTECH, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20230057166-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-112739420-A | Phenoxy-pyridyl-pyrimidine compounds and methods of use | 基因泰克公司 | 2021-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057166-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | XBP1, ERN1, ESR2 | NR1H2 146/4885NAMPT 780/4885KDM4E 2226/4885 |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | NR1H2 3723/4885NAMPT 22/4885KDM4E 2139/4885 |
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | XBP1, ERN1, ESR2 | NR1H2 146/4885NAMPT 780/4885KDM4E 2226/4885 |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | TYMP, TYMS, DPYD | NR1H2 3723/4885NAMPT 22/4885KDM4E 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.